Peginterferon Alfa-2B

證據等級: L5

預測適應症: 10 個

Peginterferon Alfa-2b: From Chronic Hepatitis C to Hepatitis B Virus Infection

One-Sentence Summary

Peginterferon alfa-2b is a pegylated recombinant interferon originally developed for chronic hepatitis C (in combination with ribavirin). The TxGNN model predicts it may also be effective for Hepatitis B Virus Infection, a use already supported by 2 completed Phase 3 RCTs, several Phase 4/real-world studies, and 19 publications, making this less a novel hypothesis than a confirmation of an already-established clinical practice in several countries.

Quick Overview

Item	Content
Original Indication	Chronic Hepatitis C (with ribavirin); melanoma (adjuvant, in some markets) — based on established public drug information; not present in this evidence pack
Predicted New Indication	Hepatitis B Virus Infection
TxGNN Prediction Score	99.84%
Evidence Level	L1
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known public information, peginterferon alfa-2b is a pegylated form of recombinant interferon alfa-2b, originally developed for chronic hepatitis C (in combination with ribavirin) and, in some markets, used as adjuvant therapy for high-risk melanoma.

Mechanistically, peginterferon alfa-2b is a type I interferon receptor agonist that induces a broad-spectrum antiviral state via the JAK-STAT pathway and exerts immunomodulatory effects, including promotion of HBV-specific T-cell responses. This is not a novel repurposing hypothesis but reflects existing clinical practice: peginterferon (alfa-2a or alfa-2b) is already used for HBeAg-positive chronic hepatitis B in multiple countries, including Taiwan and China.

Chronic hepatitis C and chronic hepatitis B are both viral hepatitides affecting the liver via RNA/DNA viral persistence, and both have historically been treated with interferon-based antiviral/immunomodulatory therapy before the direct-acting antiviral era. This shared therapeutic rationale, combined with a substantial existing clinical trial record in HBV, supports the reasonableness of the TxGNN prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00536263	Phase 3	Completed	671	RCT comparing PegIntron dosing regimens (1.0 vs 1.5 mcg/kg/week) in HBeAg-positive chronic hepatitis B; largest Phase 3 trial in this indication
NCT04846491	Phase 3	Completed	475	Multicenter randomized blinded study of peginterferon alfa-2b + tenofovir disoproxil fumarate vs. comparator in chronic hepatitis B
NCT03181113	N/A	Completed	473	Multicenter prospective cohort assessing long-term benefit of standard peginterferon alfa therapy in HBeAg-positive CHB
NCT00371761	Phase 3	Completed	25	Randomized comparative study: PegIntron vs. adefovir in HBeAg-positive CHB patients in Taiwan
NCT05182463	Phase 4	Recruiting	5000	Large real-world study (E-Cure) of peginterferon alfa-2b in inactive chronic hepatitis B patients
NCT02973646	Phase 4	Unknown	100	Antiviral effects of peginterferon alfa-2b in HBeAg-positive CHB correlated with interferon gene mutation/receptor status
NCT00686790	Phase 3	Completed	68	Open-label study of Peg-Intron in treatment-naïve chronic hepatitis B and D co-infection
NCT01532843	Phase 4	Completed	82	PEGON study: nucleos(t)ide analogue pre-treatment prior to peginterferon alfa-2b to improve sustained response in HBeAg-positive CHB
NCT00226447	Phase 2	Completed	30	Viral kinetics of pegylated interferon plus lamivudine combination therapy in HBeAg-positive CHB
NCT03332329	Phase 4	Unknown	15	Combination/sequential therapy with entecavir, peginterferon alfa-2b, and immunomodulators (GM-CSF + vaccine) targeting HBsAg loss in NA-suppressed CHB

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41366186	2026	RCT	Hepatology International	ANCHOR randomized controlled trial: entecavir + peginterferon alfa-2b ± GM-CSF combination therapy evaluating HBsAg loss rates
25200354	2014	RCT	J Clin Virol	Randomized trial of peginterferon alfa-2b in Chinese HBeAg-positive chronic hepatitis B patients
17604363	2007	RCT	Hepatology	Peginterferon alpha-2b (± lamivudine) safe and effective in HBeAg-positive CHB patients with advanced fibrosis (n=70)
16167968	2005	Systematic Review	Aliment Pharmacol Ther	Systematic review of pegylated interferon for treatment of chronic hepatitis B
24738850	2014	Review	Expert Opin Biol Ther	Review of peginterferon alfa (2a/2b) use in chronic hepatitis B, including identification of super-/null-responders
21423260	2011	Review	Nat Rev Gastroenterol Hepatol	Overview of hepatitis B therapy goals and response assessment
27190319	2016	Review	Clin Infect Dis	Virus and host testing strategies for managing chronic hepatitis B
38089868	2023	Cohort	Front Med	Scoring system predicting HBsAg clearance with peginterferon alfa-2b in NA-experienced CHB patients
40390028	2025	Cohort	Virology Journal	Multicenter pilot study of recurrence risk factors after PEG-IFN-α-2b-based functional cure
40172187	2025	Comparative Study	Microbiology Spectrum	PEG-IFNα monotherapy vs. combination with entecavir/tenofovir in 147 treatment-naïve CHB patients

Denmark Market Information

Peginterferon alfa-2b is currently not marketed in Denmark, and no marketing authorisations (national Laegemiddelstyrelsen or centralised EMA) are recorded in this evidence pack.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two completed Phase 3 RCTs (NCT00536263, n=671; NCT00371761, n=25) plus multiple Phase 4/real-world studies and 19 publications, including RCTs, a systematic review, and cohort studies, support use of peginterferon alfa-2b in chronic hepatitis B (Evidence Level L1). This is not a speculative repurposing signal but reflects an already-established international clinical practice — however, the drug is currently unmarketed in Denmark and key safety/regulatory data are missing.

To proceed, the following is needed:

Danish SmPC warnings and contraindications (currently a Blocking data gap — required before any S1 safety assessment)
Confirmed mechanism of action data from DrugBank (High-severity data gap affecting mechanistic-linkage analysis)
Drug-drug interaction data (DDI query currently returns no results)
A Danish marketing authorisation pathway assessment, since the product is not currently registered in Denmark
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.